Protein chip for lung cancer diagnosis and kit

Abstract

The invention relates to a protein chip for lung cancer diagnosis and a kit. The protein chip for the lung cancer diagnosis comprises a solid phase supporting matter and an antigen which is wrapped with the surface of the solid phase supporting matter, wherein the antigen comprises the following twelve antigen fragments: a Paxi11in antigen fragment, a CTAG1B antigen fragment, an SOX2 antigen fragment, an HSPA9 antigen fragment, a UBQLN1 antigen fragment, a C14orf104 antigen fragment, an ENO-1 antigen fragment, a RPS3 antigen fragment, a CHK antigen fragment, an HNRPA1 antigen fragment, a PCNAantigen fragment and an Eif4g3 antigen fragment. According to the protein chip and the kit, the antigens which are obviously expressed in the early lung cancer and are capable of enabling related antibody growing in the immune system are creatively selected, and the antigens are not expressed or expressed a little in non-cancer benign lesion; the screened antigen fragments are combined to use; theprotein chip technology is carried out to detect the own antibody, related to tumor, in human serum and identify benign nodule of early lung cancer and the lung; and the sensitivity and the specificity are high.

Description

technical field [0001] The invention relates to the field of cancer diagnosis and treatment, in particular to a protein chip and a kit for lung cancer diagnosis. Background technique [0002] Lung cancer is one of the malignant tumors with the fastest increasing morbidity and mortality and the greatest threat to the health and life of the population. In the past 50 years, many countries have reported that the morbidity and mortality of lung cancer have increased significantly. Currently, the diagnosis of lung cancer mainly relies on imaging (such as spiral CT) and cytology. Spiral CT can detect lung lesions more than 3nm more sensitively, but it has a high false positive rate for the diagnosis of lung cancer, especially for the identification of early lung cancer and benign pulmonary nodules. Other detection techniques, such as sputum cytology, fine-needle aspiration cytology, and fluorescent bronchoscopy, all have the disadvantages of high false positive rate, invasivenes...

AI Technical Summary

Problems solved by technology

Other detection techniques, such as sputum cytology, fine-needle aspiration cytology, and fluorescent bronchoscopy, all have disadvantages such as high false positive rate, invasiveness, and high detection cost, and cannot be used for population screening

However, the traditional ELISA detection of serum antibodies is slow and inefficient, and requires a large amount of serum samples, which is very inconvenient for specific detection.

Images